摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5,5,5-trifluoro-4-methylpentanoic acid | 915030-41-0

中文名称
——
中文别名
——
英文名称
5,5,5-trifluoro-4-methylpentanoic acid
英文别名
——
5,5,5-trifluoro-4-methylpentanoic acid化学式
CAS
915030-41-0
化学式
C6H9F3O2
mdl
——
分子量
170.131
InChiKey
FJEWRXJSGOEVHT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    5-amino-N-(4-chlorophenyl)-1,3-thiazole-4-carboxamide 、 5,5,5-trifluoro-4-methylpentanoic acid 生成 6-(4-chlorophenyl)-5-(4,4,4-trifluoro-3-methylbutyl)[1,3]thiazolo[5,4-d]pyrimidin-7(6H)-one
    参考文献:
    名称:
    Haloalkyl-substituted pyrimidinone derivatives
    摘要:
    提供了Haloalkyl-取代的嘧啶酮衍生物,其化学式为:其中变量如本文所述。这些化合物是配体,可用于调节体内或体外特定受体活性,并且在治疗与人类、家养伴侣动物和家畜动物的病理性受体激活相关的疾病方面特别有用。还提供了用于治疗此类疾病的制药组合物和方法,以及使用此类配体进行受体定位研究的方法。
    公开号:
    US20080090845A1
  • 作为产物:
    描述:
    5,5,5-三氟-4-甲基戊腈 在 sodium hydroxide 作用下, 以 甲醇 为溶剂, 反应 16.0h, 生成 5,5,5-trifluoro-4-methylpentanoic acid
    参考文献:
    名称:
    [EN] 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
    [FR] MODULATEURS ALLOSTÉRIQUES DE 5-(PYRIDIN-3-YL)OXAZOLE DU RÉCEPTEUR MUSCARINIQUE M4 DE L'ACÉTYLCHOLINE
    摘要:
    提供了含有5-(吡啶-3-基)噁唑化合物的组合物,这些化合物的组合物以及这些组合物在潜在预防或治疗M4肌胆碱受体参与的疾病中的用途。
    公开号:
    WO2019000238A1
点击查看最新优质反应信息

文献信息

  • [EN] FLUOROALKYL AND FLUOROCYCLOALKYL 1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH|INHIBITORS<br/>[FR] COMPOSÉS DE FLUORALKYL- ET DE FLUOROCYCLOALKYL-1,4-BENZODIAZÉPINONE UTILISABLES EN TANT QU'INHIBITEURS DU RÉCEPTEUR NOTCH
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2014047397A1
    公开(公告)日:2014-03-27
    Disclosed are compounds of Formula (I): (Formula (I)) wherein: R1 is -CH2CH2CF3; R2 is -CH2CH2CH2F, -CH2CF2CH3, -CH2CH2CF3, -CH2CH(CH3)CF3, -CH2CH2CF2CH3, (Formulae (II), (III), (IV), (V) or (VI): R3 is H or -CH3; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.
    公开的是Formula (I)的化合物:(Formula (I))其中:R1为-CH2CH2CF3;R2为-CH2CH2CH2F,-CH2CF2CH3,-CH2CH2CF3,-CH2CH(CH3)CF3,-CH2CH2CF2CH3,(Formulae (II),(III),(IV),(V)或(VI):R3为H或-CH3;环A为苯基或吡啶基;Rx,Ry,Ra,Rb,y和z在此处定义。还公开了使用这些化合物抑制Notch受体的方法,以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面非常有用,如癌症。
  • 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1)
    申请人:Brown Rebecca Elizabeth
    公开号:US20090298856A1
    公开(公告)日:2009-12-03
    The use of a compound of formula (I): for the manufacture of a medicament for the treatment of conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1, also known as TRPV1).
    使用化合物(I)的制剂,用于制造治疗通过调节vanilloid-1受体(VR1,又称TRPV1)功能改善的疾病的药物。
  • FLUOROALKYL AND FLUOROCYCLOALKYL 1,4-BENZODIAZEPINONE COMPOUNDS
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US20150231152A1
    公开(公告)日:2015-08-20
    Disclosed are compounds of Formula (I): (Formula (I)) wherein: R 1 is —CH 2 CH 2 CF 3 ; R 2 is —CH 2 CH 2 CH 2 F, —CH 2 CF 2 CH 3 , —CH 2 CH 2 CF 3 , —CH 2 CH(CH 3 )CF 3 , —CH 2 CH 2 CF 2 CH 3 , (Formulae (II), (III), (IV), (V) or (VI): R 3 is H or —CH 3 ; Ring A is phenyl or pyridinyl; and R x , R y , R a , R b , y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.
    本发明涉及一种式子(I)的化合物:(式子(I))其中:R1为—CH2CH2CF3;R2为—CH2CH2CH2F、—CH2CF2CH3、—CH2CH2CF3、—CH2CH(CH3)CF3、—CH2CH2CF2CH3、(式子(II)、(III)、(IV)、(V)或(VI):R3为H或—CH3;环A为苯基或吡啶基;Rx、Ry、Ra、Rb、y和z在此定义。还公开了使用这种化合物来抑制Notch受体的方法和包含这种化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或障碍方面非常有用,如癌症。
  • 5-(pyridin-3-yl)oxazole allosteric modulators of the M4 muscarinic acetylcholine receptor
    申请人:Merck Sharp & Dohme Corp.
    公开号:US10981902B2
    公开(公告)日:2021-04-20
    The present invention is directed to 5-(pyridine-3-yl)oxaxole compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    本发明涉及 5-(吡啶-3-基)氧杂吲哚化合物,它是 M4 蕈样乙酰胆碱受体的异位调节剂。本发明还涉及本文所述化合物在潜在治疗或预防涉及 M4 肌 肉碱乙酰胆碱受体的神经和精神疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及 M4 蕈样乙酰胆碱受体的此类疾病中的用途。
  • WO2006/122200
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多